|
21 Oct 2018 |
Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920, a Novel Engineered CD40L Antagonist, at the 2018 ACR/ARHP Annual Meeting
|
|
19 Oct 2018 |
Kuros Biosciences advances its Fibrin-PTH (KUR-113) spinal fusion product candidate program
|
|
19 Oct 2018 |
Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
|
|
19 Oct 2018 |
Novaliq Announces Positive Topline Results for Its CyclASol® Phase 2B/3 Essence Trial in Patients with Dry Eye Disease
|
|
19 Oct 2018 |
Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
|
|
16 Oct 2018 |
Peptilogics Receives Regulatory Approval to Initiate First-in-Human Safety Study for Therapeutic Peptide PLG0206
|
|
10 Oct 2018 |
Fresenius Kabi’s pegfilgrastim biosimilar candidate MSB11455 met its primary endpoints in the two pivotal clinical studies
|
|
06 Oct 2018 |
FDA Approves Revcovi™, a New Enzyme Replacement Therapy Developed by Leadiant Biosciences, for the Treatment of ADA-SCID in Pediatric and Adult Patients
|
|
04 Oct 2018 |
Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
|
|
02 Oct 2018 |
Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes
|
|
02 Oct 2018 |
Inotrem Announces Positive Results From the Phase IIa Study of Its Lead Compound, Nangibotide (LR12), in the Treatment of Septic Shock
|
|
02 Oct 2018 |
Torque Announces the Presentation of Preclinical Data for Deep IL-15 Primed T Cells Demonstrating Superior T Cell Expansion, Persistence, and Safety Compared with Systemically Administered IL-15
|
|
02 Oct 2018 |
FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
|
|
30 Sep 2018 |
New phase 2 data for somapacitan demonstrate its potential as an efficacious once-weekly treatment for childhood growth hormone deficiency
|
|
27 Sep 2018 |
Horizon Pharma plc Initiates Clinical Trial to Evaluate KRYSTEXXA® (pegloticase injection) with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout
|
|
27 Sep 2018 |
Hansa Medical Reports Positive Final Top Line Results from Two Phase 2 Studies of Imlifidase for Kidney Transplantation
|
|
27 Sep 2018 |
Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children
|
|
26 Sep 2018 |
Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis
|
|
26 Sep 2018 |
Coherus BioSciences Receives European Commission Approval for UDENYCA™ (Pegfilgrastim Biosimilar)
|
|
26 Sep 2018 |
Bydureon receives positive EU CHMP opinion for EXSCEL cardiovascular outcomes data
|
|
24 Sep 2018 |
AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis
|
|
21 Sep 2018 |
Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
|
|
21 Sep 2018 |
Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease
|
|
21 Sep 2018 |
Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim
|
|
21 Sep 2018 |
Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027
|
